Paeonol alleviates ulcerative colitis in mice by increasing short-chain fatty acids derived from Clostridium butyricum

被引:19
作者
Zhao, Meng [1 ]
Xie, Xueqian [1 ]
Xu, Bo [1 ]
Chen, Yunliang [1 ]
Cai, Yanping [1 ]
Chen, Kehan [1 ]
Guan, Xinling [1 ]
Ni, Chen [1 ]
Luo, Xia [1 ]
Zhou, Lian [1 ]
机构
[1] Guangzhou Univ Chinese Med, Sch Pharmaceut Sci, Guangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
Paeonol; Clostridium butyricum; DSS-induced colitis; Intestinal barrier; Short chain fatty acids; INFLAMMATORY BOWEL DISEASES;
D O I
10.1016/j.phymed.2023.155056
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Background: Increasing evidence suggests that repairing the damaged intestinal epithelial barrier and restoring its function is the key to solving the problem of prolonged ulcerative colitis. Previous studies have shown that paeonol (pae) can alleviate colitis by down-regulating inflammatory pathways. In addition, pae also has a certain effect on regulating intestinal flora. However, it remains unclear whether pae can play a role in repairing the intestinal barrier and whether there is a relationship between the therapeutic effect and the gut microbiota. Purposes: The aim of this study is to investigate the effect of pae on intestinal barrier repair in UC mice and how the gut microbiota plays a part in it. Study Design and Methods: The therapeutic effect of pae was evaluated in a 3% DSS-induced UC mouse model. The role of pae in repairing the intestinal barrier was evaluated by detecting colonic cupped cells by Alcian blue staining, the expression of colonic epithelial tight junction protein by immunofluorescence and western blot, and the proportion of IL-22(+)ILC3 cells in the lamina propria lymphocytes by flow cytometry. Subsequently, 16S rRNA sequencing was used to observe the changes in intestinal flora, GC-MS was used to detect the level of SCFAs, and qPCR was used to identify the abundance of Clostridium butyricum in the intestine to evaluate the effect of pae on the gut microbiota. The antibiotic-mediated depletion of the gut flora was then used to verify that pae depends on C. butyricum to play a healing role. Finally, non-targeted metabolomics was employed to investigate the potential pathways of pae regulating C. butyricum. Results: Pae could improve intestinal microecological imbalance and promote the production of short-chain fatty acids (SCFAs). Most importantly, we identified C. butyricum as a key bacterium responsible for the intestinal barrier repair effect of pae in UC mice. Eradication of intestinal flora by antibiotics abolished the repair of the intestinal barrier and the promotion of SCFAs production by pae, while C. butyricum colonization could restore the therapeutic effects of pae in UC mice, which further confirmed that C. butyricum was indeed the "driver bacterium" of pae in UC treatment. Untargeted metabolomics showed that pae regulated some amino acid metabolism and 2-Oxocarboxylic acid metabolism in C. butyricum. Conclusions: Our study showed that the restoration of the impaired intestinal barrier by pae to alleviate colitis is associated with increased C. butyricum and SCFAs production, which may be a promising strategy for the treatment of UC.
引用
收藏
页数:15
相关论文
共 35 条
[1]   Mucosal Healing in Ulcerative Colitis: A Comprehensive Review [J].
Carvalho, Pedro Boal ;
Cotter, Jose .
DRUGS, 2017, 77 (02) :159-173
[2]   Pathophysiology of Inflammatory Bowel Diseases [J].
Chang, John T. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (27) :2652-2664
[3]   Metabolite-Sensing Receptor Ffar2 Regulates Colonic Group 3 Innate Lymphoid Cells and Gut Immunity [J].
Chun, Eunyoung ;
Lavoie, Sydney ;
Fonseca-Pereira, Diogo ;
Bae, Sena ;
Michaud, Monia ;
Hoveyda, Hamid R. ;
Fraser, Graeme L. ;
Comeau, Carey Ann Gallini ;
Glickman, Jonathan N. ;
Fuller, Miles H. ;
Layden, Brian T. ;
Garrett, Wendy S. .
IMMUNITY, 2019, 51 (05) :871-+
[4]   Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study [J].
Clooney, Adam G. ;
Eckenberger, Julia ;
Laserna-Mendieta, Emilio ;
Sexton, Kathryn A. ;
Bernstein, Matthew T. ;
Vagianos, Kathy ;
Sargent, Michael ;
Ryan, Feargal J. ;
Moran, Carthage ;
Sheehan, Donal ;
Sleator, Roy D. ;
Targownik, Laura E. ;
Bernstein, Charles N. ;
Shanahan, Fergus ;
Claesson, Marcus J. .
GUT, 2021, 70 (03) :499-510
[5]   Short chain fatty acids and its producing organisms: An overlooked therapy for IBD? [J].
Deleu, Sara ;
Machiels, Kathleen ;
Raes, Jeroen ;
Verbeke, Kristin ;
Vermeire, Severine .
EBIOMEDICINE, 2021, 66
[6]   Dihydromyricetin improves DSS-induced colitis in mice via modulation of fecal-bacteria-related bile acid metabolism [J].
Dong, Sijing ;
Zhu, Min ;
Wang, Ke ;
Zhao, Xiaoye ;
Hu, Longlong ;
Jing, Wanghui ;
Lu, Haitao ;
Wang, Sicen .
PHARMACOLOGICAL RESEARCH, 2021, 171
[7]   Dextran sodium sulfate colitis murine model: An indispensable tool for advancing our understanding of inflammatory bowel diseases pathogenesis [J].
Eichele, Derrick D. ;
Kharbanda, Kusum K. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (33) :6016-6029
[8]   Impact of Bacterial Metabolites on Gut Barrier Function and Host Immunity: A Focus on Bacterial Metabolism and Its Relevance for Intestinal Inflammation [J].
Gasaly, Naschla ;
de Vos, Paul ;
Hermoso, Marcela A. .
FRONTIERS IN IMMUNOLOGY, 2021, 12
[9]   Interleukin-22 protects intestinal stem cells against genotoxic stress [J].
Gronke, Konrad ;
Hernandez, Pedro P. ;
Zimmermann, Jakob ;
Klose, Christoph S. N. ;
Kofoed-Branzk, Michael ;
Guendel, Fabian ;
Witkowski, Mario ;
Tizian, Caroline ;
Amann, Lukas ;
Schumacher, Fabian ;
Glatt, Hansruedi ;
Triantafyllopoulou, Antigoni ;
Diefenbach, Andreas .
NATURE, 2019, 566 (7743) :249-+
[10]   Review: emerging drug therapies in inflammatory bowel disease [J].
Grossberg, Laurie B. ;
Papamichael, Konstantinos ;
Cheifetz, Adam S. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (07) :789-804